An Alnylam spokesperson said the company was evaluating its options and may appeal. A BioNTech spokesperson said the filing "confirms Pfizer's and BioNTech's position that we do not infringe any ...

Alnylam Pharmaceuticals has landed a long-awaited FDA decision that expands use of its drug, Amvuttra, to the treatment of a type of cardiomyopathy that’s growing in prevalence. It’s the ...

Alnylam Pharmaceuticals (ALNY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

Alnylam concedes its inability to secure a judgment against Moderna’s products after the court’s claim construction. Moderna’s counterclaims and affirmative defenses were dismissed without ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on ...

You can reach Adam on Signal at stataf.54. I coined the term “Typo-gate” to describe the misguided dustup Alnylam Pharmaceuticals executives instigated last Friday when they asserted ...

Alnylam stock soared 31% on positive Phase 3 trial news and continued rising afterward. Getting vutrisiran, which is marketed as Amvuttra, to market for this new condition just might make ...

Getty Images Alnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular events. The ...

Alnylam reported mixed fourth-quarter results. The company also announced changes to its Helios-B phase 3 study of vutrisiran in ATTR-CM. Today's sell-off could present a buying opportunity for ...

Alnylam's shares have seen significant growth, up over 140% since September 2019. The company has secured approvals for five RNAi drugs and aims to become a top-tier biotech company by 2025. The ...